Research programme: cancer and diabetic foot ulcer therapeutics - Aurealis Pharma

Drug Profile

Research programme: cancer and diabetic foot ulcer therapeutics - Aurealis Pharma

Alternative Names: AUP 100 series; AUP 16; AUP 500 series

Latest Information Update: 03 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aurealis Pharma
  • Class Antibodies; Recombinant proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer; Diabetic foot ulcer

Highest Development Phases

  • Preclinical Diabetic foot ulcer
  • Research Cancer

Most Recent Events

  • 15 Feb 2016 Early research in Cancer in Finland (unspecified route)
  • 15 Feb 2016 Preclinical trials in Diabetic foot ulcer in Finland (unspecified route)
  • 15 Feb 2016 Aurealis Pharma plans a first-in-man trial for Diabetic foot ulcer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top